Cargando…
Impact of the Norepinephrine Prodrug Droxidopa on the QTc Interval in Healthy Individuals
A double‐blind, 4‐period crossover study (NCT01327066) was conducted to assess the effect of the novel norepinephrine prodrug droxidopa on the QT interval in in healthy subjects. Subjects were randomized to receive a single dose of droxidopa 600 mg (maximal dose) and 2000 mg (supratherapeutic dose)...
Autores principales: | White, William B., Hewitt, L. Arthur, Mehdirad, Ali A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901008/ https://www.ncbi.nlm.nih.gov/pubmed/29024579 http://dx.doi.org/10.1002/cpdd.393 |
Ejemplares similares
-
Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Goodman, Brent P., et al.
Publicado: (2017) -
Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
por: Gupta, Fiona, et al.
Publicado: (2017) -
Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension
por: Mehdirad, Ali, et al.
Publicado: (2017) -
Erratum to: Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
por: Gupta, Fiona, et al.
Publicado: (2017) -
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
por: Biaggioni, Italo, et al.
Publicado: (2017)